XML 73 R41.htm IDEA: XBRL DOCUMENT v3.19.3
Collaborative and Other Relationships (Tables)
9 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Activity Related to BAN2401 and Elenbecestat Collaboration
A summary of development expense related to the BAN2401 and Elenbecestat Collaboration is as follows:
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
(In millions)
2019
 
2018
 
2019
 
2018
Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat
$
168.7

 
$
64.9

 
$
305.3

 
$
176.0

Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income
$
84.3

 
$
32.5

 
$
152.6

 
$
88.0


Summary of Activity Related to Aducanumab Collaboration
A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
(In millions)
2019
 
2018
 
2019
 
2018
Total aducanumab development expense
$
4.7

 
$
64.8

 
$
170.5

 
$
204.8

Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income
$
2.6

 
$
55.1

 
$
93.8

 
$
183.6

 
 
 
 
 
 
 
 
Total aducanumab sales and marketing expense incurred by the collaboration
$
0.1

 
$
12.1

 
$
21.3

 
$
33.3

Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income
$

 
$
5.1

 
$
11.7

 
$
19.0